Your browser is no longer supported. Please, upgrade your browser.
ALEC Alector, Inc. monthly Stock Chart
ALEC [NASD]
Alector, Inc.
Index- P/E- EPS (ttm)-2.23 Insider Own0.40% Shs Outstand78.77M Perf Week9.93%
Market Cap1.03B Forward P/E- EPS next Y-2.76 Insider Trans-8.85% Shs Float65.55M Perf Month33.43%
Income-168.60M PEG- EPS next Q-0.66 Inst Own78.30% Short Float15.91% Perf Quarter4.81%
Sales22.20M P/S46.38 EPS this Y-125.00% Inst Trans-1.59% Short Ratio12.07 Perf Half Y-59.36%
Book/sh3.94 P/B3.37 EPS next Y-11.30% ROA-31.40% Target Price- Perf Year-26.82%
Cash/sh5.96 P/C2.23 EPS next 5Y- ROE-53.90% 52W Range9.12 - 35.93 Perf YTD-22.87%
Dividend- P/FCF- EPS past 5Y- ROI-58.80% 52W High-63.01% Beta-
Dividend %- Quick Ratio6.60 Sales past 5Y- Gross Margin- 52W Low45.72% ATR0.62
Employees162 Current Ratio6.60 Sales Q/Q118.50% Oper. Margin- RSI (14)67.17 Volatility3.82% 5.66%
OptionableYes Debt/Eq0.00 EPS Q/Q-42.40% Profit Margin- Rel Volume0.44 Prev Close13.23
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume864.21K Price13.29
Recom1.60 SMA2013.81% SMA5019.18% SMA200-35.40% Volume376,364 Change0.45%
Jun-24-20Initiated H.C. Wainwright Buy $41
Apr-28-20Initiated Goldman Buy $32
Mar-06-20Initiated Citigroup Buy $40
Feb-27-20Initiated Barclays Overweight $36
Feb-19-20Initiated Stifel Buy $44
Nov-21-19Initiated BTIG Research Buy $28
Mar-04-19Initiated SVB Leerink Outperform
Mar-04-19Initiated Morgan Stanley Overweight $27
Mar-04-19Initiated BofA/Merrill Buy $26
Mar-04-19Initiated Barclays Overweight $27
Nov-12-20 11:18AM  
Nov-11-20 04:05PM  
Nov-10-20 06:45PM  
04:05PM  
Nov-09-20 05:30AM  
Nov-03-20 12:30PM  
Nov-02-20 07:44AM  
Oct-22-20 04:05PM  
Oct-06-20 08:54AM  
Sep-24-20 11:46AM  
Sep-16-20 03:23PM  
Sep-13-20 08:53AM  
Sep-03-20 04:05PM  
Aug-11-20 05:55PM  
04:05PM  
Aug-04-20 08:30AM  
Aug-03-20 12:31PM  
Jul-29-20 01:00PM  
07:32AM  
Jul-28-20 06:00PM  
Jul-24-20 06:12PM  
08:30AM  
Jul-21-20 05:00PM  
05:00PM  
Jul-15-20 07:31AM  
Jun-28-20 07:16PM  
Jun-25-20 09:00AM  
Jun-12-20 07:00PM  
Jun-03-20 04:01PM  
May-16-20 08:05AM  
May-13-20 09:25AM  
08:00AM  
May-07-20 08:30AM  
May-04-20 08:20AM  
May-03-20 07:00AM  
Apr-02-20 11:30AM  
Mar-31-20 10:34AM  
Mar-26-20 06:11AM  
Mar-25-20 05:00PM  
Mar-24-20 05:25PM  
04:05PM  
Mar-23-20 08:30AM  
Mar-17-20 12:30PM  
12:00PM  
11:30AM  
Mar-11-20 09:53AM  
Mar-06-20 07:25PM  
Feb-28-20 08:51AM  
Feb-24-20 08:30AM  
Feb-06-20 07:47AM  
Feb-05-20 08:00AM  
07:21AM  
Feb-03-20 06:00PM  
Jan-31-20 09:09AM  
08:00AM  
Jan-29-20 09:42PM  
Jan-28-20 08:30AM  
Jan-27-20 04:05PM  
Jan-17-20 08:45PM  
Jan-08-20 08:30AM  
Jan-06-20 08:30AM  
Dec-27-19 02:57PM  
Dec-20-19 08:30AM  
Dec-13-19 06:30AM  
06:28AM  
Dec-12-19 07:08PM  
Dec-11-19 04:05PM  
Dec-06-19 04:30PM  
07:39AM  
Dec-05-19 04:22PM  
Dec-04-19 09:15AM  
Nov-14-19 08:30AM  
Nov-12-19 04:05PM  
Nov-11-19 09:28AM  
Oct-28-19 07:46PM  
Sep-23-19 01:22PM  
Sep-20-19 10:02AM  
Sep-19-19 06:56AM  
Sep-09-19 08:00AM  
Sep-03-19 04:10PM  
Aug-12-19 04:10PM  
09:00AM  
Jul-18-19 10:26AM  
Jul-17-19 04:05PM  
Jul-11-19 06:30AM  
Jun-26-19 09:04PM  
Jun-14-19 12:03PM  
May-13-19 04:26PM  
04:05PM  
May-08-19 04:05PM  
02:15PM  
May-06-19 06:30AM  
May-01-19 05:43PM  
Apr-22-19 12:28AM  
Apr-17-19 04:05PM  
Apr-15-19 03:00PM  
Apr-10-19 08:00AM  
Apr-09-19 05:49PM  
Apr-04-19 09:17AM  
Apr-03-19 09:58AM  
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer's disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Paul RobertChief Medical OfficerJul 15Sale22.9610,000229,642213,719Jul 17 04:43 PM
MCGUIRE TERRANCEDirectorJun 23Sale31.544,377138,06312,853,817Jun 25 05:53 PM
Polaris Venture Management Co.10% OwnerJun 23Sale31.544,377138,06312,853,817Jun 25 05:47 PM
Paul RobertChief Medical OfficerJun 15Sale29.6110,000296,137223,719Jun 17 04:21 PM
Yu CalvinVice President, FinanceJun 03Sale31.261,34341,981110,686Jun 05 04:40 PM
King RobertChief Development OfficerMay 15Sale27.0015,000404,958477,317May 19 05:23 PM
Paul RobertChief Medical OfficerMay 15Sale27.0010,000270,026233,719May 19 05:23 PM
ORBIMED ADVISORS LLC10% OwnerApr 16Sale23.5362,1831,463,1661,906,718Apr 16 08:23 PM
Paul RobertChief Medical OfficerApr 15Sale22.2710,000222,700243,719Apr 17 05:12 PM
ORBIMED ADVISORS LLC10% OwnerApr 14Sale23.5223,231546,3931,921,804Apr 16 08:23 PM
ORBIMED ADVISORS LLC10% OwnerApr 09Sale23.79288,1016,853,9231,927,440Apr 09 05:30 PM
ORBIMED ADVISORS LLC10% OwnerApr 08Sale23.6582,6141,953,8211,997,333Apr 09 05:30 PM
ORBIMED ADVISORS LLC10% OwnerApr 07Sale23.109,170211,8272,017,374Apr 09 05:30 PM
ORBIMED ADVISORS LLC10% OwnerMar 31Sale24.50250,0006,125,0002,019,598Apr 02 05:06 PM
ORBIMED ADVISORS LLC10% OwnerMar 25Sale24.6656,4111,391,0952,080,243Mar 25 05:54 PM
ORBIMED ADVISORS LLC10% OwnerMar 24Sale24.4567,6441,653,8962,093,927Mar 25 05:54 PM
ORBIMED ADVISORS LLC10% OwnerMar 23Sale26.0514,598380,2782,110,336Mar 25 05:54 PM
Paul RobertChief Medical OfficerMar 13Sale22.9310,000229,286253,719Mar 17 07:07 PM
ORBIMED ADVISORS LLC10% OwnerMar 02Sale26.001,874,20348,729,2780Mar 04 04:17 PM
King RobertChief Development OfficerFeb 14Sale29.5615,000443,376492,317Feb 18 05:00 PM
Paul RobertChief Medical OfficerFeb 14Sale29.5410,000295,390263,719Feb 18 05:00 PM
Yu CalvinVice President, FinanceFeb 07Option Exercise9.5910,22598,088134,719Feb 10 04:42 PM
Oney SabahChief Business OfficerFeb 07Sale35.0319,900697,097573,918Feb 11 05:53 PM
Yu CalvinVice President, FinanceFeb 07Sale35.0224,033841,636110,686Feb 10 04:42 PM
Yu CalvinVice President, FinanceFeb 06Option Exercise8.951,82116,295127,115Feb 10 04:42 PM
Oney SabahChief Business OfficerFeb 06Sale35.001003,500593,818Feb 06 05:48 PM
Yu CalvinVice President, FinanceFeb 06Sale35.002,62191,735124,494Feb 10 04:42 PM
Paul RobertChief Medical OfficerFeb 05Option Exercise8.1610,00081,600283,719Feb 07 08:11 PM
Paul RobertChief Medical OfficerFeb 05Sale32.1010,000321,000273,719Feb 07 08:11 PM
Yu CalvinVice President, FinanceFeb 04Option Exercise8.1613,541110,495188,835Feb 06 05:18 PM
Oney SabahChief Business OfficerFeb 04Option Exercise8.1616,667136,003610,585Feb 06 05:48 PM
Oney SabahChief Business OfficerFeb 04Sale30.0016,667500,010593,918Feb 06 05:48 PM
SCHELLER RICHARD HDirectorFeb 04Sale29.6710,000296,7009,981Feb 06 05:19 PM
Yu CalvinVice President, FinanceFeb 04Sale30.0463,5411,908,772125,294Feb 06 05:18 PM
Wehner David M.DirectorFeb 03Buy25.0020,000500,00044,621Feb 03 06:19 PM
Paul RobertChief Medical OfficerJan 30Option Exercise8.168,00065,280281,719Feb 03 06:14 PM
Paul RobertChief Medical OfficerJan 30Sale28.008,000224,000273,719Feb 03 06:14 PM
Oney SabahChief Business OfficerJan 27Option Exercise8.1614,467118,051608,385Jan 27 05:41 PM
Oney SabahChief Business OfficerJan 27Sale25.0514,467362,398593,918Jan 27 05:41 PM
Paul RobertChief Medical OfficerJan 23Option Exercise8.166,00048,960279,719Jan 27 05:15 PM
Oney SabahChief Business OfficerJan 23Option Exercise8.162,20017,952596,118Jan 27 05:41 PM
Oney SabahChief Business OfficerJan 23Sale25.212,20055,462593,918Jan 27 05:41 PM
Paul RobertChief Medical OfficerJan 23Sale24.326,000145,919273,719Jan 27 05:15 PM
King RobertChief Development OfficerJan 22Sale22.01366507,317Jan 23 04:48 PM
King RobertChief Development OfficerJan 21Sale22.0114,997330,084507,320Jan 23 04:48 PM
Paul RobertChief Medical OfficerJan 15Sale18.6710,000186,700273,719Jan 17 04:53 PM
ORBIMED ADVISORS LLC10% OwnerJan 09Sale19.50379,9977,409,94238,808Jan 13 04:48 PM
ORBIMED ADVISORS LLC10% OwnerDec 26Sale18.6010,800200,88040,200Dec 26 04:54 PM
ORBIMED ADVISORS LLC10% OwnerDec 24Sale19.5971,8001,406,56241,400Dec 26 04:54 PM
ORBIMED ADVISORS LLC10% OwnerDec 23Sale19.8294,2851,868,72949,400Dec 26 04:54 PM
ORBIMED ADVISORS LLC10% OwnerDec 20Sale19.66342,5006,733,55059,800Dec 26 04:54 PM
ORBIMED ADVISORS LLC10% OwnerDec 17Sale18.52954,10017,669,93297,700Dec 19 04:33 PM
Paul RobertChief Medical OfficerDec 13Sale20.0310,000200,300283,719Dec 17 05:33 PM
Oney SabahChief Business OfficerDec 12Option Exercise8.166,81055,570600,728Dec 16 08:13 PM
Oney SabahChief Business OfficerDec 12Sale20.136,810137,069593,918Dec 16 08:13 PM
Oney SabahChief Business OfficerDec 10Option Exercise8.165004,080594,418Dec 12 04:34 PM
Oney SabahChief Business OfficerDec 10Sale20.0150010,005593,918Dec 12 04:34 PM
Oney SabahChief Business OfficerDec 09Option Exercise8.162,30018,768596,218Dec 09 06:36 PM
Oney SabahChief Business OfficerDec 09Sale20.072,30046,161593,918Dec 09 06:36 PM
Oney SabahChief Business OfficerDec 06Option Exercise8.165,15642,073599,074Dec 09 06:36 PM
Oney SabahChief Business OfficerDec 06Sale20.025,156103,223593,918Dec 09 06:36 PM
Oney SabahChief Business OfficerDec 05Option Exercise8.161,50012,240595,418Dec 09 06:36 PM
Oney SabahChief Business OfficerDec 05Sale20.001,50030,000593,918Dec 09 06:36 PM
Yu CalvinVice President, FinanceDec 03Sale18.311,31524,078175,294Dec 05 04:25 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.